Document is current

Article History

Received: 22 December 2025

Accepted: 21 June 2026

First Online: 1 August 2026

Declarations

Conflict of Interest: Catherine Tregunno, Quentin Deraedt, Susanna Cuadripani, Céline Verheust, and Philip Bryan are employed by GSK and hold financial equities in GSK. The authors declare no other financial or non-financial relationships or activities.

Ethics Approval: Not applicable; this review was based solely on spontaneously reported adverse events from GSK’s global safety database.

Consent to Participate: Not applicable.

Consent for Publication: Not applicable.

Availability of Data and Material: The data that support the findings of this review are available from the corresponding author upon reasonable request.

Code Availability: Not applicable.

Authors’ contributions: All authors were involved in the conceptualization and design of the review. All authors were involved in the analysis and interpretation of the data. All authors reviewed and commented on the drafts of the manuscript for intellectual content. All authors read and approved the final version. All authors attest they meet the ICMJE criteria for authorship.

Meeting(s) Where the Information has Previously been Presented: The interim results of this work were presented at IDWeek, 16–19 October, 2024, in Los Angeles, CA, USA. Available at: .

Trademark Statement: Arexvy and AS01 are trademarks owned by or licensed to the GSK group of companies. Abrysvo is a trademark of Pfizer and mRESVIA is a trademark of Moderna.